# Synthetic mechanoreceptor engineering: From genetic encoding to DNA nanotechnology-based reprogramming

**Authors:** Sihui Yang, Zhou Nie

PMC · DOI: 10.1016/j.mbm.2025.100160 · 2025-10-06

## TL;DR

This paper reviews how synthetic mechanoreceptors can be engineered using genetic and DNA nanotechnology methods to control cell signaling and fate.

## Contribution

The paper introduces DNA-functionalized artificial mechanoreceptors that enable force-responsiveness in non-mechanosensitive receptors without genetic modification.

## Key findings

- Genetic encoding and site-directed mutagenesis reprogram natural mechanoreceptors' force-response functions.
- DNA nanotechnology enables precise control over receptor spatial organization and signal transduction.
- DNA-based artificial mechanoreceptors offer a non-genetic approach for customized mechanotransduction applications.

## Abstract

Precise modulation of mechanoreceptor-mediated signal transduction is crucial for decoding cellular mechanotransduction mechanisms and programming cell fate. This review provides a comprehensive summary of recent advances in engineering synthetic mechanoreceptors, spanning from protein-centric genetic encoding to DNA nanotechnology-based non-genetic reprogramming strategies. Genetic engineering strategies employ protein structure encoding and site-directed mutagenesis to reprogram force-response functions in natural mechanoreceptors. As a complementary non-genetic approach, DNA nanotechnology leverages its programmability, modularity, and predictable mechanical properties to achieve precise control over receptor functionalities. The flourishing development of DNA mechanosensitive nanodevices has provided a promising synthetic toolkit for manipulating mechanoreceptors, enabling precise control over receptor spatial organization and signal transduction. A key innovation is the development of novel DNA-functionalized artificial mechanoreceptors (AMRs), which confer force-responsiveness to naturally non-mechanosensitive receptors without genetic modification, thereby enabling customized mechanotransduction and mechanobiological applications. Collectively, this paradigm shift highlights DNA-based non-genetic receptor engineering as a versatile and powerful toolkit, paving new avenues for mechanobiology research and pioneering force-directed therapeutic strategies in regenerative medicine.

Image 1

## Full-text entities

- **Genes:** CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}, ITGAL (integrin subunit alpha L) [NCBI Gene 3683] {aka CD11A, EV6, HNA-5, LFA-1, LFA1A}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, VCL (vinculin) [NCBI Gene 7414] {aka CMD1W, CMH15, HEL114, MV, MVCL, VINC}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CTNND1 (catenin delta 1) [NCBI Gene 1500] {aka BCDS2, CAS, CTNND, P120CAS, P120CTN, p120}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}
- **Diseases:** tumor metastasis (MESH:D009362), cardiovascular diseases (MESH:D002318), inflammatory (MESH:D007249), fibrosis (MESH:D005355), cancer (MESH:D009369), AMR (MESH:D060437)
- **Chemicals:** RGD (MESH:C047981), HAVDI (-), lipid (MESH:D008055), calcium (MESH:D002118), polymer (MESH:D011108)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12552974/full.md

---
Source: https://tomesphere.com/paper/PMC12552974